{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:17:32Z","timestamp":1790695052741,"version":"4.1.0"},"reference-count":70,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T00:00:00Z","timestamp":1643760000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>The EMPA-REG OUTCOME (Empagliflozin, Cardiovascular Outcome Event Trial in patients with Type 2 Diabetes Mellitus (T2DM)) trial evidenced the potential of sodium-glucose cotransporter 2 (SGLT2) inhibitors for the treatment of patients with diabetes and cardiovascular disease. Recent evidences have shown the benefits of the SGLT2 inhibitor empagliflozin on improving liver steatosis and fibrosis in patients with T2DM. Metabolomic studies have been shown to be very useful to improve the understanding of liver pathophysiology during the development and progression of metabolic hepatic diseases, and because the effects of empagliflozin and of other SGLT2 inhibitors on the complete metabolic profile of the liver has never been analysed before, we decided to study the impact on the liver of male Zucker diabetic fatty (ZDF) rats of a treatment for 6\u00a0weeks with empagliflozin using an untargeted metabolomics approach, with the purpose to help to clarify the benefits of the use of empagliflozin at hepatic level. We found that empagliflozin is able to change the hepatic lipidome towards a protective profile, through an increase of monounsaturated and polyunsaturated glycerides, phosphatidylcholines, phosphatidylethanolamines, lysophosphatidylinositols and lysophosphatidylcholines. Empagliflozin also induces a decrease in the levels of the markers of inflammation IL-6, chemerin and chemerin receptor in the liver. Our results provide new evidences regarding the molecular pathways through which empagliflozin could exert hepatoprotector beneficial effects in T2DM.<\/jats:p>","DOI":"10.3389\/fphar.2022.827033","type":"journal-article","created":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T05:24:17Z","timestamp":1643779457000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["The Treatment With the SGLT2 Inhibitor Empagliflozin Modifies the Hepatic Metabolome of Male Zucker Diabetic Fatty Rats Towards a Protective Profile"],"prefix":"10.3389","volume":"13","author":[{"given":"Alana","family":"Arag\u00f3n-Herrera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Otero-Santiago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Anido-Varela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Mora\u00f1a-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Campos-Toimil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom\u00e1s","family":"Garc\u00eda-Caballero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Barral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estefan\u00eda","family":"Taraz\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Rosell\u00f3-Llet\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Portol\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oreste","family":"Gualillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Moscoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Lage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Ram\u00f3n","family":"Gonz\u00e1lez-Juanatey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Feij\u00f3o-Band\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisca","family":"Lago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,2,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"113677","DOI":"10.1016\/j.bcp.2019.113677","article-title":"Empagliflozin Reduces the Levels of CD36 and Cardiotoxic Lipids while Improving Autophagy in the Hearts of Zucker Diabetic Fatty Rats","volume":"170","author":"Arag\u00f3n-Herrera","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1038\/oby.2009.379","article-title":"Decreased Liver Fatty Acid delta-6 and delta-5 Desaturase Activity in Obese Patients","volume":"18","author":"Araya","year":"2010","journal-title":"Obesity (Silver Spring)"},{"key":"B3","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1139\/apnm-2012-0261","article-title":"Nonalcoholic Fatty Liver Disease Is Associated with Lower Hepatic and Erythrocyte Ratios of Phosphatidylcholine to Phosphatidylethanolamine","volume":"38","author":"Arendt","year":"2013","journal-title":"Appl. Physiol. Nutr. Metab."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1021\/pr201223p","article-title":"Obesity-dependent Metabolic Signatures Associated with Nonalcoholic Fatty Liver Disease Progression","volume":"11","author":"Barr","year":"2012","journal-title":"J. Proteome Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"4501","DOI":"10.1021\/pr1002593","article-title":"Liquid Chromatography-Mass Spectrometry-Based Parallel Metabolic Profiling of Human and Mouse Model Serum Reveals Putative Biomarkers Associated with the Progression of Nonalcoholic Fatty Liver Disease","volume":"9","author":"Barr","year":"2010","journal-title":"J. Proteome Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"15010","DOI":"10.1038\/ncomms15010","article-title":"Thermogenic Adipocytes Promote HDL Turnover and Reverse Cholesterol Transport","volume":"8","author":"Bartelt","year":"2017","journal-title":"Nat. Commun."},{"key":"B7","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/obr.12333","article-title":"Association of Recently Described Adipokines with Liver Histology in Biopsy-Proven Non-alcoholic Fatty Liver Disease: a Systematic Review","volume":"17","author":"Bekaert","year":"2016","journal-title":"Obes. Rev."},{"key":"B8","doi-asserted-by":"publisher","first-page":"100284","DOI":"10.1016\/j.jhepr.2021.100284","article-title":"Genetic Predisposition Similarities between NASH and ASH: Identification of New Therapeutic Targets","volume":"3","author":"Bianco","year":"2021","journal-title":"JHEP Rep."},{"key":"B9","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.diabet.2018.09.005","article-title":"Effects of SGLT2 Inhibitors on Systemic and Tissue Low-Grade Inflammation: The Potential Contribution to Diabetes Complications and Cardiovascular Disease","volume":"44","author":"Bonnet","year":"2018","journal-title":"Diabetes Metab."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1042\/BST20140138","article-title":"Deciphering Non-alcoholic Fatty Liver Disease through Metabolomics","volume":"42","author":"Cano","year":"2014","journal-title":"Biochem. Soc. Trans."},{"key":"B11","doi-asserted-by":"publisher","first-page":"46658","DOI":"10.1038\/srep46658","article-title":"Metabolism Dysregulation Induces a Specific Lipid Signature of Nonalcoholic Steatohepatitis in Patients","volume":"7","author":"Chiappini","year":"2017","journal-title":"Sci. Rep."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1194\/jlr.M028902","article-title":"Lipidomic Analysis of Lipid Droplets from Murine Hepatocytes Reveals Distinct Signatures for Nutritional Stress","volume":"53","author":"Chitraju","year":"2012","journal-title":"J. Lipid Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/liv.14350","article-title":"A Diabetologist's Perspective of Non-alcoholic Steatohepatitis (NASH): Knowledge Gaps and Future Directions","volume":"40","author":"Cusi","year":"2020","journal-title":"Liver Int."},{"key":"B14","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.jacc.2018.10.058","article-title":"Chemerin as a Biomarker Linking Inflammation and Cardiovascular Diseases","volume":"73","author":"Eichelmann","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s10557-018-6786-x","article-title":"Do the SGLT-2 Inhibitors Offer More Than Hypoglycemic Activity","volume":"32","author":"Flores","year":"2018","journal-title":"Cardiovasc. Drugs Ther."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1007\/s40265-018-0937-z","article-title":"Empagliflozin: A Review in Type 2 Diabetes","volume":"78","author":"Frampton","year":"2018","journal-title":"Drugs"},{"key":"B17","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1002\/hep.25601","article-title":"Absence of Adipose Triglyceride Lipase Protects from Hepatic Endoplasmic Reticulum Stress in Mice","volume":"56","author":"Fuchs","year":"2012","journal-title":"Hepatology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1038\/s41591-019-0675-0","article-title":"Chronic Inflammation in the Etiology of Disease across the Life Span","volume":"25","author":"Furman","year":"2019","journal-title":"Nat. Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1007\/s00125-021-05442-2","article-title":"Liver-targeting Drugs and Their Effect on Blood Glucose and Hepatic Lipids","volume":"64","author":"Gastaldelli","year":"2021","journal-title":"Diabetologia"},{"key":"B20","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1530\/JOE-18-0076","article-title":"Multiple Effects of Cold Exposure on Livers of Male Mice","volume":"238","author":"Grefhorst","year":"2018","journal-title":"J. Endocrinol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1161\/ATVBAHA.117.309660","article-title":"\u0394-5 Fatty Acid Desaturase FADS1 Impacts Metabolic Disease by Balancing Proinflammatory and Proresolving Lipid Mediators","volume":"38","author":"Gromovsky","year":"2018","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1002\/hep.28953","article-title":"Lipid Zonation and Phospholipid Remodeling in Nonalcoholic Fatty Liver Disease","volume":"65","author":"Hall","year":"2017","journal-title":"Hepatology"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e111348","DOI":"10.1371\/journal.pone.0111348","article-title":"Alterations of Plasma Lysophosphatidylcholine Species in Obesity and Weight Loss","volume":"9","author":"Heimerl","year":"2014","journal-title":"PLoS One"},{"key":"B24","doi-asserted-by":"publisher","first-page":"R79","DOI":"10.1530\/JOE-18-0174","article-title":"Chemerin: a Multifaceted Adipokine Involved in Metabolic Disorders","volume":"238","author":"Helfer","year":"2018","journal-title":"J. Endocrinol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3389\/FMED.2019.00202","article-title":"Cardiovascular Risk in Fatty Liver Disease: The Liver-Heart Axis-Literature Review","volume":"6","author":"Ismaiel","year":"2019","journal-title":"Front. Med. (Lausanne)"},{"key":"B26","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.cca.2020.02.008","article-title":"Chemerin in Immune Response and Gastrointestinal Pathophysiology","volume":"504","author":"Jacenik","year":"2020","journal-title":"Clin. Chim. Acta"},{"key":"B27","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13098-016-0169-x","article-title":"Empagliflozin (An SGLT2 Inhibitor), Alone or in Combination with Linagliptin (A DPP-4 Inhibitor), Prevents Steatohepatitis in a Novel Mouse Model of Non-alcoholic Steatohepatitis and Diabetes","volume":"8","author":"Jojima","year":"2016","journal-title":"Diabetol. Metab. Syndr."},{"key":"B28","doi-asserted-by":"publisher","first-page":"106779","DOI":"10.1016\/j.vph.2020.106779","article-title":"Anti-inflammatory Effects of Sodium-Glucose Co-transporter 2 Inhibitors on Atherosclerosis","author":"Kang","year":"2020","journal-title":"Vascul Pharmacol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1111\/j.1476-5381.2010.00872.x","article-title":"NC3Rs Reporting Guidelines Working GroupAnimal Research: Reporting In Vivo Experiments: the ARRIVE Guidelines","volume":"160","author":"Kilkenny","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1530\/EC-21-0273","article-title":"Determinants of Elevated Chemerin as a Novel Biomarker of Immunometabolism: Data from a Large Population-Based Cohort","volume":"10","author":"Koelman","year":"2021","journal-title":"Endocr. Connect."},{"key":"B31","doi-asserted-by":"publisher","first-page":"203","DOI":"10.2337\/db08-1074","article-title":"Hepatic Stearoyl-CoA Desaturase (SCD)-1 Activity and Diacylglycerol but Not Ceramide Concentrations Are Increased in the Nonalcoholic Human Fatty Liver","volume":"58","author":"Kotronen","year":"2009","journal-title":"Diabetes"},{"key":"B32","doi-asserted-by":"publisher","first-page":"8364","DOI":"10.3748\/wjg.v20.i26.8364","article-title":"Experimental Models of Non-alcoholic Fatty Liver Disease in Rats","volume":"20","author":"Kucera","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.2337\/dc18-0165","article-title":"Effect of Empagliflozin on Liver Fat in Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)","volume":"41","author":"Kuchay","year":"2018","journal-title":"Diabetes Care"},{"key":"B34","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/joim.13380","article-title":"Inflammatory and Fibrotic Mechanisms in NAFLD-Implications for New Treatment Strategies","volume":"291","author":"Lee","year":"2021","journal-title":"J. Intern. Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.2337\/dc12-1760","article-title":"Circulating Lysophosphatidylcholines Are Markers of a Metabolically Benign Nonalcoholic Fatty Liver","volume":"36","author":"Lehmann","year":"2013","journal-title":"Diabetes Care"},{"key":"B36","doi-asserted-by":"publisher","first-page":"111504","DOI":"10.1016\/j.mce.2021.111504","article-title":"Role of Chemerin in the Control of Glucose Homeostasis","volume":"541","author":"L\u00e9niz","year":"2022","journal-title":"Mol. Cell Endocrinol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.tem.2021.04.008","article-title":"Links between Metabolic Syndrome and Metabolic Dysfunction-Associated Fatty Liver Disease","volume":"32","author":"Lim","year":"2021","journal-title":"Trends Endocrinol. Metab."},{"key":"B38","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1002\/lipd.12236","article-title":"Lipid Profiles of Five Essential Phospholipid Preparations for the Treatment of Nonalcoholic Fatty Liver Disease: A Comparative Study","volume":"55","author":"L\u00fcchtenborg","year":"2020","journal-title":"Lipids"},{"key":"B39","doi-asserted-by":"publisher","first-page":"e16717","DOI":"10.1097\/MD.0000000000016717","article-title":"Serum Metabolome and Targeted Bile Acid Profiling Reveals Potential Novel Biomarkers for Drug-Induced Liver Injury","volume":"98","author":"Ma","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"B40","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.jprot.2015.01.019","article-title":"Enhancing Metabolomics Research through Data Mining","volume":"127","author":"Mart\u00ednez-Arranz","year":"2015","journal-title":"J. Proteomics"},{"key":"B41","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1146\/annurev.nutr.24.121803.063211","article-title":"Structure, Function, and Dietary Regulation of delta6, delta5, and delta9 Desaturases","volume":"24","author":"Nakamura","year":"2004","journal-title":"Annu. Rev. Nutr."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms22020818","article-title":"Empagliflozin Attenuates Non-alcoholic Fatty Liver Disease (NAFLD) in High Fat Diet Fed ApoE(-\/-) Mice by Activating Autophagy and Reducing ER Stress and Apoptosis","volume":"22","author":"Nasiri-Ansari","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.bbalip.2011.06.021","article-title":"Phosphatidylcholine Protects against Steatosis in Mice but Not Non-alcoholic Steatohepatitis","volume":"1811","author":"Niebergall","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.2337\/db16-1410","article-title":"Correcting Postprandial Hyperglycemia in Zucker Diabetic Fatty Rats With an SGLT2 Inhibitor Restores Glucose Effectiveness in the Liver and Reduces Insulin Resistance in Skeletal Muscle","volume":"66","author":"O\u2019Brien","year":"2017","journal-title":"Diabetes"},{"key":"B44","doi-asserted-by":"publisher","first-page":"799","DOI":"10.3390\/nu11040799","article-title":"Fatty Acid Desaturase Involvement in Non-alcoholic Fatty Liver Disease Rat Models: Oxidative Stress versus Metalloproteinases","volume":"11","author":"Palladini","year":"2019","journal-title":"Nutrients"},{"key":"B45","doi-asserted-by":"publisher","first-page":"188","DOI":"10.3390\/METABO11030188","article-title":"Stable Isotopic Tracer Phospholipidomics Reveals Contributions of Key Phospholipid Biosynthetic Pathways to Low Hepatocyte Phosphatidylcholine to Phosphatidylethanolamine Ratio Induced by Free Fatty Acids","volume":"11","author":"Peng","year":"2021","journal-title":"Metabolites"},{"key":"B46","doi-asserted-by":"publisher","first-page":"6332","DOI":"10.3390\/ijms22126332","article-title":"Empagliflozin Improves Metabolic and Hepatic Outcomes in a Non-diabetic Obese Biopsy-Proven Mouse Model of Advanced NASH","volume":"22","author":"Perakakis","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B47","doi-asserted-by":"publisher","first-page":"R95","DOI":"10.1152\/ajpregu.00112.2020","article-title":"Characterization of the Circulating and Tissue-specific Alterations to the Lipidome in Response to Moderate and Major Cold Stress in Mice","volume":"320","author":"Pernes","year":"2021","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"110539","DOI":"10.1016\/j.mce.2019.110539","article-title":"Empaglifozin Mitigates NAFLD in High-Fat-Fed Mice by Alleviating Insulin Resistance, Lipogenesis and ER Stress","volume":"498","author":"Petito-da-Silva","year":"2019","journal-title":"Mol. Cel. Endocrinol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"154001","DOI":"10.1016\/j.metabol.2019.154001","article-title":"Effects of Newer Antidiabetic Drugs on Nonalcoholic Fatty Liver and Steatohepatitis: Think Out of the Box!","volume":"101","author":"Ranjbar","year":"2019","journal-title":"Metabolism"},{"key":"B50","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1210\/jc.2015-3525","article-title":"Lipidomics Reveals Associations of Phospholipids with Obesity and Insulin Resistance in Young Adults","volume":"101","author":"Rauschert","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B51","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/978-1-62703-068-7_8","article-title":"Diabetes in Zucker Diabetic Fatty Rat","volume-title":"Animal Models in Diabetes Research","author":"Shiota","year":"2012"},{"key":"B52","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1172\/JCI62308","article-title":"Brown Adipose Tissue Regulates Glucose Homeostasis and Insulin Sensitivity","volume":"123","author":"Stanford","year":"2013","journal-title":"J. Clin. Invest."},{"key":"B53","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.redox.2017.06.009","article-title":"The SGLT2 Inhibitor Empagliflozin Improves the Primary Diabetic Complications in ZDF Rats","volume":"13","author":"Steven","year":"2017","journal-title":"Redox Biol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.cca.2021.02.010","article-title":"Chemerin in Inflammatory Diseases","volume":"517","author":"Su","year":"2021","journal-title":"Clin. Chim. Acta"},{"key":"B55","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.freeradbiomed.2019.05.029","article-title":"Lipidomic Biomarkers and Mechanisms of Lipotoxicity in Non-alcoholic Fatty Liver Disease","volume":"144","author":"Svegliati-Baroni","year":"2019","journal-title":"Free Radic. Biol. Med."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1007\/s10741-020-09954-8","article-title":"Comparative Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) for Cardiovascular Outcomes in Type 2 Diabetes: a Systematic Review and Network Meta-Analysis of Randomised Controlled Trials","volume":"26","author":"T\u00e4ger","year":"2020","journal-title":"Heart Fail. Rev."},{"key":"B57","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1136\/gutjnl-2020-320853","article-title":"Loss of Hepatic Mboat7 Leads to Liver Fibrosis","volume":"70","author":"Thangapandi","year":"2021","journal-title":"Gut"},{"key":"B70","doi-asserted-by":"publisher","first-page":"E1225","DOI":"10.1152\/ajpendo.00507.2013","article-title":"Glucotoxicity Targets Hepatic Glucokinase in Zucker Diabetic Fatty Rats, a Model of Type 2 Diabetes Associated With Obesity","volume":"306","author":"Ueta","year":"2014","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"B58","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1038\/s41366-018-0189-8","article-title":"Plasma Lipid Profiling of Tissue-specific Insulin Resistance in Human Obesity","volume":"43","author":"van der Kolk","year":"2019","journal-title":"Int. J. Obes. (Lond)"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1016\/j.bbamem.2017.04.006","article-title":"The Critical Role of Phosphatidylcholine and Phosphatidylethanolamine Metabolism in Health and Disease","volume":"1859","author":"van der Veen","year":"2017","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"B60","doi-asserted-by":"publisher","first-page":"5045","DOI":"10.1096\/fj.201802117R","article-title":"A Role for Phosphatidylcholine and Phosphatidylethanolamine in Hepatic Insulin Signaling","volume":"33","author":"van der Veen","year":"2019","journal-title":"FASEB J."},{"key":"B61","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","article-title":"SGLT2 Inhibitors and Mechanisms of Cardiovascular Benefit: a State-Of-The-Art Review","volume":"61","author":"Verma","year":"2018","journal-title":"Diabetologia"},{"key":"B62","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1111\/dom.14196","article-title":"A Look to the Future in Non-alcoholic Fatty Liver Disease: Are Glucagon-like Peptide-1 Analogues or Sodium-Glucose Co-transporter-2 Inhibitors the Answer","volume":"22","author":"Vincent","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"B63","doi-asserted-by":"publisher","first-page":"10986","DOI":"10.1096\/fj.201900679R","article-title":"Hepatic PEMT Activity Mediates Liver Health, Weight Gain, and Insulin Resistance","volume":"33","author":"Wan","year":"2019","journal-title":"FASEB J."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1210\/er.2019-00034","article-title":"The Liver as an Endocrine Organ-Linking NAFLD and Insulin Resistance","volume":"40","author":"Watt","year":"2019","journal-title":"Endocr. Rev."},{"key":"B65","doi-asserted-by":"publisher","first-page":"e000783","DOI":"10.1136\/bmjdrc-2019-000783","article-title":"Empagliflozin Reverses Obesity and Insulin Resistance through Fat browning and Alternative Macrophage Activation in Mice Fed a High-Fat Diet","volume":"7","author":"Xu","year":"2019","journal-title":"BMJ Open Diabetes Res. Care"},{"key":"B66","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1002\/hep4.1322","article-title":"Serum Metabolomic Profiling Identifies Key Metabolic Signatures Associated with Pathogenesis of Alcoholic Liver Disease in Humans","volume":"3","author":"Yang","year":"2019","journal-title":"Hepatol. Commun."},{"key":"B67","doi-asserted-by":"publisher","first-page":"8258","DOI":"10.1074\/jbc.M710422200","article-title":"Identification and Characterization of a Major Liver Lysophosphatidylcholine Acyltransferase","volume":"283","author":"Zhao","year":"2008","journal-title":"J. Biol. Chem."},{"key":"B68","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.827033\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T05:24:20Z","timestamp":1643779460000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.827033\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,2]]},"references-count":70,"alternative-id":["10.3389\/fphar.2022.827033"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.827033","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,2]]},"article-number":"827033"}}